Xinran Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinran Cheng has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yue Hu
Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications - Zheng Li
Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
5 shared publications Weilan He
Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
3 shared publicationsJing Zhang
2 shared publications- Cuixia Di
Bio-Medical Research Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China
1 shared publication Jie Leng
1 shared publication
Latest Publications
- 1 September 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
Epigenetic dysregulation in differences in sex development
Introduction: Sex development is precisely orchestrated by genetic and epigenetic mechanisms; disruption of this intricate process leads to differences in sex development (DSD). Content: n this review, we systematically examine the role of epigenetic mechanisms in DSD, including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling. Unlike previous reviews focused predominantly on animal models, we integrate available epigenetic evidence from human DSD patients and attempt to distinguish causative changes from secondary consequences. Endocrine-disrupting chemicals (EDCs) have been partially validated in animal models to affect gonadal and reproductive functions through epigenetic mechanisms, but human evidence remains limited. Summary and Outlook: Finally, we cautiously propose a diagnostic workflow that integrates epigenetic testing and attempt to identify key gaps in current research and suggest testable directions for future studies.
- 1 September 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
Epigenetic dysregulation in differences in sex development
Introduction: Sex development is precisely orchestrated by genetic and epigenetic mechanisms; disruption of this intricate process leads to differences in sex development (DSD). Content: n this review, we systematically examine the role of epigenetic mechanisms in DSD, including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling. Unlike previous reviews focused predominantly on animal models, we integrate available epigenetic evidence from human DSD patients and attempt to distinguish causative changes from secondary consequences. Endocrine-disrupting chemicals (EDCs) have been partially validated in animal models to affect gonadal and reproductive functions through epigenetic mechanisms, but human evidence remains limited. Summary and Outlook: Finally, we cautiously propose a diagnostic workflow that integrates epigenetic testing and attempt to identify key gaps in current research and suggest testable directions for future studies.
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (8) , 330
Whole-exome sequencing-centered genetic evaluation for early-onset obesity in Chinese children: a retrospective single-center cohort
Background: Genetic causes of early-onset obesity remain undercharacterized in East Asian children. This study evaluated a whole-exome sequencing (WES)-centered diagnostic workflow in Chinese children with obesity onset before 5 years. Methods: Consecutive children with body mass index above the 95th percentile and obesity onset before 5 years who completed structured inpatient assessment at a single center between February 2022 and December 2023 were retrospectively analyzed. Phenotyping included clinical, biochemical, oral glucose tolerance, cortisol rhythm, and liver assessments. Genetic testing combined WES, mitochondrial DNA analysis, multiplex ligation-dependent probe amplification (MLPA) for obesity-related imprinting loci, WES-based copy-number variant and runs-of-homozygosity analyses, and Sanger validation. Variants were interpreted according to the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criteria. Results: Among 23 children, clinically relevant genetic findings were identified in 6 (26.1%): melanocortin-4 receptor (MC4R) c.831T>A (p.C277*), maternal uniparental disomy of 15q11–13, and four phenotype-correlated variants of uncertain significance in UCP3, BBS1, NCOA1, and SH2B1. The definitive/likely diagnostic yield, restricted to pathogenic or confirmed imprinting findings, was 8.7% (2/23). Findings involved leptin-MC4R signaling, BBSome function, fatty-acid oxidation, and chromosomal imprinting. Genetically positive children showed numerically higher alanine aminotransferase (ALT) and aspartate aminotransferase (AST), but differences were not statistically significant. BBS1 p.T374S was relatively enriched in East Asian reference data. Conclusions: A WES-centered integrated workflow detected heterogeneous genetic mechanisms in Chinese children with early-onset obesity, but variant of uncertain significance (VUS)-associated findings should be distinguished from confirmed diagnoses. Orthogonal methylation/MLPA and runs of homozygosity (ROH) analyses were necessary for imprinting diagnosis. Larger multicenter studies and functional validation are needed.
- 1 August 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (8) , 330
Open AccessWhole-exome sequencing-centered genetic evaluation for early-onset obesity in Chinese children: a retrospective single-center cohort
Background: Genetic causes of early-onset obesity remain undercharacterized in East Asian children. This study evaluated a whole-exome sequencing (WES)-centered diagnostic workflow in Chinese children with obesity onset before 5 years. Methods: Consecutive children with body mass index above the 95th percentile and obesity onset before 5 years who completed structured inpatient assessment at a single center between February 2022 and December 2023 were retrospectively analyzed. Phenotyping included clinical, biochemical, oral glucose tolerance, cortisol rhythm, and liver assessments. Genetic testing combined WES, mitochondrial DNA analysis, multiplex ligation-dependent probe amplification (MLPA) for obesity-related imprinting loci, WES-based copy-number variant and runs-of-homozygosity analyses, and Sanger validation. Variants were interpreted according to the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criteria. Results: Among 23 children, clinically relevant genetic findings were identified in 6 (26.1%): melanocortin-4 receptor (MC4R) c.831T>A (p.C277*), maternal uniparental disomy of 15q11–13, and four phenotype-correlated variants of uncertain significance in UCP3, BBS1, NCOA1, and SH2B1. The definitive/likely diagnostic yield, restricted to pathogenic or confirmed imprinting findings, was 8.7% (2/23). Findings involved leptin-MC4R signaling, BBSome function, fatty-acid oxidation, and chromosomal imprinting. Genetically positive children showed numerically higher alanine aminotransferase (ALT) and aspartate aminotransferase (AST), but differences were not statistically significant. BBS1 p.T374S was relatively enriched in East Asian reference data. Conclusions: A WES-centered integrated workflow detected heterogeneous genetic mechanisms in Chinese children with early-onset obesity, but variant of uncertain significance (VUS)-associated findings should be distinguished from confirmed diagnoses. Orthogonal methylation/MLPA and runs of homozygosity (ROH) analyses were necessary for imprinting diagnosis. Larger multicenter studies and functional validation are needed.
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (3) , 90
Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome with aplasia cutis congenita due to PIK3R2 mutations: case report
Background: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome is a rare congenital developmental disorder characterized by megalencephaly, polymicrogyria, posterior polydactyly, and hydrocephalus and driven by PI3K-AKT-mTOR pathway dysregulation. This report presents a case of genetically confirmed MPPH in which the patient also exhibited aplasia cutis congenita (ACC), a cutaneous phenotype rarely described in this syndrome. Case Description: We describe a full-term female infant with macrocephaly [head circumference > +2 standard deviations (SDs)] and distinctive craniofacial features, including a prominent forehead, hypertelorism, and a low nasal bridge. Neuroimaging revealed bilateral perisylvian polymicrogyria, while developmental assessment indicated mild-to-moderate delay across multiple domains. Genetic testing identified a heterozygous c.1117G>A (p.G373R) mutation in PIK3R2 and confirmed it to be MPPH syndrome. Notably, a well-demarcated area of ACC was observed on the anterior neck. The patient was also found to have a patent ductus arteriosus (PDA). Such clinical findings have infrequently been described in the existing medical literature. Conclusions: This report highlights the co-occurrence of ACC and PDA in a patient with PIK3R2-related MPPH, suggesting a potential expansion of the phenotypic spectrum associated with this syndrome and may provide valuable reference for early diagnosis and genetic counseling. Continued systematic documentation and synthesis of the phenotypic spectrum are vital to strengthening diagnostic consensus for this rare disease.
- 1 March 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (3) , 90
Open AccessMegalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome with aplasia cutis congenita due to PIK3R2 mutations: case report
Background: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome is a rare congenital developmental disorder characterized by megalencephaly, polymicrogyria, posterior polydactyly, and hydrocephalus and driven by PI3K-AKT-mTOR pathway dysregulation. This report presents a case of genetically confirmed MPPH in which the patient also exhibited aplasia cutis congenita (ACC), a cutaneous phenotype rarely described in this syndrome. Case Description: We describe a full-term female infant with macrocephaly [head circumference > +2 standard deviations (SDs)] and distinctive craniofacial features, including a prominent forehead, hypertelorism, and a low nasal bridge. Neuroimaging revealed bilateral perisylvian polymicrogyria, while developmental assessment indicated mild-to-moderate delay across multiple domains. Genetic testing identified a heterozygous c.1117G>A (p.G373R) mutation in PIK3R2 and confirmed it to be MPPH syndrome. Notably, a well-demarcated area of ACC was observed on the anterior neck. The patient was also found to have a patent ductus arteriosus (PDA). Such clinical findings have infrequently been described in the existing medical literature. Conclusions: This report highlights the co-occurrence of ACC and PDA in a patient with PIK3R2-related MPPH, suggesting a potential expansion of the phenotypic spectrum associated with this syndrome and may provide valuable reference for early diagnosis and genetic counseling. Continued systematic documentation and synthesis of the phenotypic spectrum are vital to strengthening diagnostic consensus for this rare disease.
- 4 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , E96-E97
Letter to the Editor: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD
- 4 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , E96-E97
Letter to the Editor: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD
- Open Access
- 1 March 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (3) , 694
How to explain the conflicting reports on all-cause mortality in the comparison of MASLD-only group with no-SLD group?
- 1 March 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (3) , 694
Open AccessHow to explain the conflicting reports on all-cause mortality in the comparison of MASLD-only group with no-SLD group?
- 24 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E21-E22
Letter to the Editor: Aspirin and GLP-1RAs—The missing confounders of empagliflozin for MASLD without diabetes mellitus?
An abstract is unavailable. This article is available as a PDF only.
- 24 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E21-E22
Letter to the Editor: Aspirin and GLP-1RAs—The missing confounders of empagliflozin for MASLD without diabetes mellitus?
An abstract is unavailable. This article is available as a PDF only.
- 5 June 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (5) , E74-E75
Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival
An abstract is unavailable. This article is available as a PDF only.
- 5 June 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (5) , E74-E75
Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (48) , e36169
Sotos syndrome treated with traditional Chinese medicine and rehabilitation: Case report
Rationale: Sotos syndrome is an congenital overgrowth syndrome characterized by the primary features including overgrowth, distinctive facial features, learning disability, and accompanied with various second features. NSD1 deletion or mutation is a major pathogenic cause. Although there are some reports on treatment of this disease worldwide, less cases under treatment have been published in China. Patient concerns: A 1-year-old boy had macrocephaly, gigantism, excessive high body height, a particular face and delayed development, with a pathogenic gene of NSD1 (NM_022455.5:c.3536delA in exon 5). Diagnosis and interventions: The child was definitely diagnosed as Sotos syndrome and have 3 months’ combination treatment of traditional Chinese medicine and rehabilitation. Outcomes: The child made a great progress in global development. Lessons: This case firstly describes the traditional Chinese medicine and rehabilitation to treat Sotos syndrome in China. There is no radical cure, but our therapy could improve the prognosis and the life quality of the patient. Therefore, this case provides a reference to the clinical treatment of Sotos syndrome.
- 1 December 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (48) , e36169
Open AccessSotos syndrome treated with traditional Chinese medicine and rehabilitation: Case report
Rationale: Sotos syndrome is an congenital overgrowth syndrome characterized by the primary features including overgrowth, distinctive facial features, learning disability, and accompanied with various second features. NSD1 deletion or mutation is a major pathogenic cause. Although there are some reports on treatment of this disease worldwide, less cases under treatment have been published in China. Patient concerns: A 1-year-old boy had macrocephaly, gigantism, excessive high body height, a particular face and delayed development, with a pathogenic gene of NSD1 (NM_022455.5:c.3536delA in exon 5). Diagnosis and interventions: The child was definitely diagnosed as Sotos syndrome and have 3 months’ combination treatment of traditional Chinese medicine and rehabilitation. Outcomes: The child made a great progress in global development. Lessons: This case firstly describes the traditional Chinese medicine and rehabilitation to treat Sotos syndrome in China. There is no radical cure, but our therapy could improve the prognosis and the life quality of the patient. Therefore, this case provides a reference to the clinical treatment of Sotos syndrome.
- Open Access
- 17 July 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (4) , E76-E77
Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
An abstract is unavailable. This article is available as a PDF only.
- 17 July 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (4) , E76-E77
Open AccessLetter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
An abstract is unavailable. This article is available as a PDF only.
- 11 May 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (2) , E29-E30
Letter to the Editor: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations
An abstract is unavailable. This article is available as a PDF only.
- 11 May 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (2) , E29-E30
Letter to the Editor: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations
An abstract is unavailable. This article is available as a PDF only.